MDXXF (Pharmala Biotech Holdings) LT-Debt-to-Total-Asset: 0.00 (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDXXF Pharmala Biotech Holdings Inc MDXXF
33 GF Score
Price $0.12
GF Value $0.13
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Pharmala Biotech Holdings LT-Debt-to-Total-Asset?

Pharmala Biotech Holdings MDXXF +7.80% 33 LT-Debt-to-Total-Asset is 0.00 as of Feb. 2026. GuruFocus rates MDXXF with a GF Score™ of 33/100 and a GF Value™ of $0.13 (Modestly Undervalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Pharmala Biotech Holdings's long-term debt to total assests ratio for the quarter that ended in Feb. 2026 was 0.00.

Pharmala Biotech Holdings's long-term debt to total assets ratio stayed the same from Feb. 2025 (0.00) to Feb. 2026 (0.00).

Pharmala Biotech Holdings  (OTCPK:MDXXF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Pharmala Biotech Holdings LT-Debt-to-Total-Asset Related Terms

Pharmala Biotech Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Pharmala Biotech Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings LT-Debt-to-Total-Asset Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
LT-Debt-to-Total-Asset
0.00 0.00 0.00 0.00 0.00

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MDXXF
33GF Score
Pharmala Biotech Holdings Inc MDXXF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmala Biotech Holdings LT-Debt-to-Total-Asset Calculation

Pharmala Biotech Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Aug. 2025 is calculated as

LT Debt to Total Assets (A: Aug. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Aug. 2025 )/Total Assets (A: Aug. 2025 )
=0/2.479
=0.00

Pharmala Biotech Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2026 is calculated as

LT Debt to Total Assets (Q: Feb. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Feb. 2026 )/Total Assets (Q: Feb. 2026 )
=0/2.293
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Pharmala Biotech Holdings (MDXXF) has a LT-Debt-to-Total-Asset of 0.00 as of Feb. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Pharmala Biotech Holdings and its competitors.
Is Pharmala Biotech Holdings' LT-Debt-to-Total-Asset too high?
Pharmala Biotech Holdings' current LT-Debt-to-Total-Asset is 0.00. Overall, Pharmala Biotech Holdings has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Pharmala Biotech Holdings' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Pharmala Biotech Holdings and its competitors. Pharmala Biotech Holdings's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.13, compared to a current price of $0.12 — trading 9.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Pharmala Biotech Holdings' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current LT-Debt-to-Total-Asset is 0.00 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.12 is trading 9.6% below its estimated GF Value™ of $0.13. GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.

Key valuation signals for MDXXF:

  • LT-Debt-to-Total-Asset: 0.00
  • GF Value™: $0.13 vs. price of $0.12 (9.6% below fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
33GF Score

Get the complete analysis for MDXXF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price
$0.13
GF Value